Gold Falls 1%; ProKidney Shares Spike Higher

Written by Emily J. Thompson, Senior Investment Analyst

APGE-6.39%

NDRA-5%

BGL-5.88%

Source: Benzinga

Updated: Jul 08 2025

0mins

Source: Benzinga

U.S. Stock Market Performance: U.S. stocks showed mixed results with the Dow Jones dropping over 150 points, while energy shares rose by 2.1%. Notable stock movements included ENDRA Life Sciences surging 134% and ProKidney Corp gaining 218%, while Sunrun Inc. fell 11% due to policy changes affecting clean-energy tax credits.
International Market Trends: European and Asian markets closed higher, with significant gains in indices such as the eurozone's STOXX 600 and Japan's Nikkei. Additionally, the U.S. Manheim Used Vehicle Value Index increased by 1.6% month-over-month for June, indicating a recovery following a decline in May.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy APGE?" and start using high-conviction signals backed by rigorous historical data.

Sign up today to access powerful investing tools and make smarter, data-driven decisions.

APGE

$65.51+Infinity%1D

Analyst Views on APGE

Wall Street analysts forecast APGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APGE is 102.50 USD with a low forecast of 70.00 USD and a high forecast of 137.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

14 Analyst Rating

13 Buy

1 Hold

0 Sell

Strong Buy

Current: 69.980

Low

70.00

Averages

102.50

High

137.00

Current: 69.980

Low

70.00

Averages

102.50

High

137.00

Citi

Buy

maintain

$95

2026-01-25

Reason

Citi

Price Target

$95

AI Analysis

2026-01-25

maintain

Buy

Reason

Citi says Friday's selloff in shares of Apogee Therapeutics (APGE) following Sanofi's (SNY) Phase 3 amlitelimab data is an overreaction. The firm is a buyer of the stock on the pullback. Citi believes the readout is not negative for the company's APG279, a fixed dose combination targeting both IL-13 and OX40L. Sanofi's readout confirms that OX40L monotherapy is not positioned to threaten Apogee's zumilokibart, the analyst tells investors in a research note. Citi keeps a Buy rating on Apogee with a $95 price target. The stock closed Friday down 12% to $70.02.

UBS

Michael Yee

Buy

maintain

$100

2026-01-25

Reason

UBS

Michael Yee

Price Target

$100

2026-01-25

maintain

Buy

Reason

UBS analyst Michael Yee says Apogee Therapeutics (APGE) sold off Friday following Sanofi's (SNY) positive Phase III OX40L data in moderate to severe atopic dermatitis. Some investors highlighted the single Kaposi's sarcoma case in Sanofi's data, viewing it as a potential negative readthrough for Apogee, since the company also has IL-13 plus OX40L combo data coming in Q3, the analyst tells investors in a research note. However, UBS does not see any meaningful readthrough to Apogee from Sanofi's data. While Kaposi's sarcoma is a potential risk to the OX40 class, the risk appears to be relatively low, contends the firm. It points out Sanofi treated thousands of patients and there was only one case of Kaposi's sarcoma, and that the patient high risk patient according to the company. UBS views the selloff as a buying opportunity and keeps a Buy rating on Apogee with a $100 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for APGE

Unlock Now

About APGE

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for APGE?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy APGE?

Get Started Free